Stay updated on Selinexor Maintenance in p53 Wild-Type Endometrial Carcinoma Clinical Trial
Sign up to get notified when there's something new on the Selinexor Maintenance in p53 Wild-Type Endometrial Carcinoma Clinical Trial page.

Latest updates to the Selinexor Maintenance in p53 Wild-Type Endometrial Carcinoma Clinical Trial page
- ChecktodayNo Change Detected
- Check7 days agoChange DetectedGlossary toggle added; page metadata updated to include Last Update Submitted that Met QC Criteria and Last Update Posted. The revision is updated to v3.4.0 and older No FEAR Act data entries were removed.SummaryDifference0.0%

- Check15 days agoChange Detected- Revision: v3.3.4 is now displayed, replacing Revision: v3.3.3. This is a minor metadata update that does not alter the study content or how users interact with the page.SummaryDifference0.0%

- Check36 days agoChange DetectedRecruitment status updated to Recruiting with new contacts added: Rebecca Brooks; Principal Investigator Joan Tymon-Rosario; and investigators Prafull Ghatage and Wei-Yu Chen (cwycwy600222@gmail.com). Removed Not yet Recruiting listings for Steven Bisch and Yin-Hsun Feng (yinhsun.feng@gmail.com).SummaryDifference0.3%

- Check44 days agoChange DetectedThe Study Details page now lists a broad set of recruitment sites across the US, Canada, Australia, and Europe (e.g., Alabama, Athens, Elm Park, Gipuzkoa, Ankara), replacing the previous locations list.SummaryDifference0.8%

- Check65 days agoChange DetectedAdded a note that publications are auto-filled from PubMed and updated the revision to v3.3.2. Removed the older PubMed-origin publications description that referenced revision v3.2.0.SummaryDifference0.0%

- Check79 days agoChange DetectedStudy Locations updated: added 'Tainan, Taiwan, 71004' and removed 'Tainan City, Taiwan, 71004' from the locations list.SummaryDifference0.1%

Stay in the know with updates to Selinexor Maintenance in p53 Wild-Type Endometrial Carcinoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Selinexor Maintenance in p53 Wild-Type Endometrial Carcinoma Clinical Trial page.